A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II formula III, formula IV, formula V, formula VI, formula VII, and formula VIII and the methods for the treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II formula III, formula IV, formula V, formula VI, formula VII, and formula VIII and the methods for the treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers.

This invention relates to an improved hydrolysis process for the preparation of dicarboxylic acids in which an organic phase comprising triglycerides of carboxylic acids having more than one acid functional group and a mixture comprising dicarboxylic acids, glycerine and partial esters of glycerine are mixed with water and hydrolysed at temperatures of between 50 and 350° C., and at pressures of or above the equilibrium vapor pressure. This process makes it possible to obtain high hydrolysis yields, even in short times.

This invention relates to an improved hydrolysis process for the preparation of dicarboxylic acids in which an organic phase comprising triglycerides of carboxylic acids having more than one acid functional group and a mixture comprising dicarboxylic acids, glycerine and partial esters of glycerine are mixed with water and hydrolysed at temperatures of between 50 and 350° C., and at pressures of or above the equilibrium vapor pressure. This process makes it possible to obtain high hydrolysis yields, even in short times.

This invention relates to an improved hydrolysis process for the preparation of dicarboxylic acids in which an organic phase comprising triglycerides of carboxylic acids having more than one acid functional group and a mixture comprising dicarboxylic acids, glycerine and partial esters of glycerine are mixed with water and hydrolysed at temperatures of between 50 and 350° C., and at pressures of or above the equilibrium vapor pressure. This process makes it possible to obtain high hydrolysis yields, even in short times.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.